	US 12,480,141 B2
	Type V Cas proteins and applications thereof
Antonio Casini, Trento (IT); Antonio Carusillo, Trento (IT); Veronica Pinamonti, Trento (IT); Matteo Ciciani, Schio (IT); and Maddalena Bosetti, Terre d'Adige (IT)
Assigned to Alia Therapeutics Srl, Milan (IT)
Filed by Alia Therapeutics Srl, Milan (IT)
Filed on Jun. 9, 2025, as Appl. No. 19/232,045.
Application 19/232,045 is a continuation of application No. PCT/EP2025/059128, filed on Apr. 3, 2025.
Claims priority of provisional application 63/574,354, filed on Apr. 4, 2024.
Prior Publication US 2025/0313864 A1, Oct. 9, 2025
Int. Cl. C12N 15/90 (2006.01); C12N 9/22 (2006.01); C12N 15/11 (2006.01)

CPC C12N 15/907 (2013.01) [C12N 9/226 (2025.05); C12N 15/11 (2013.01); C07K 2319/09 (2013.01); C12N 2310/20 (2017.05)]

23 Claims

1. A fusion protein comprising:

(a) a Type V Cas amino acid sequence comprising an amino acid sequence that is at least 98% identical to the full length of SEQ ID NO:43 or SEQ ID NO:44; and

(b) one or more nuclear localization signals.